Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008 Jun;103(6):1048-50.
doi: 10.1111/j.1360-0443.2008.02209.x.

Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)

Edward W Boyer  1 , Kavita M Babu, Jessica E Adkins, Christopher R McCurdy, John H Halpern
Affiliations
Case Reports

Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth)

Edward W Boyer et al. Addiction. 2008 Jun.

Abstract

Background: Kratom (Mitragynia speciosa korth) is recognized increasingly as a remedy for opioid withdrawal by individuals who self-treat chronic pain.

Case description: A patient who had abruptly ceased injection hydromorphone abuse self-managed opioid withdrawal and chronic pain using kratom. After co-administering the herb with modafinil he experienced a tonic-clonic seizure, but he reported only modest abstinence once kratom administration stopped. We confirmed the identity of the plant matter he ingested as kratom and identified no contaminants or adulterants. We also conducted high-throughput molecular screening and the binding affinity at mu, delta and kappa receptors of mitragynine.

Conclusion: We report the self-treatment of chronic pain and opioid withdrawal with kratom. The predominant alkaloid of kratom, mitragynine, binds mu- and kappa-opioid receptors, but has additional receptor affinities that might augment its effectiveness at mitigating opioid withdrawal. The natural history of kratom use, including its clinical pharmacology and toxicology, are poorly understood.

PubMed Disclaimer

References

    1. Boyer E, Babu K, Macalino G, Compton W. Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict. 2007;16:352–6. - PubMed
    1. Yamamoto L, Horie S, Takayama H, Aimi N, Sakai S. Opioid receptor agonistic characteristics of mytragynine pseudoindoxyl in comparison with mitragyine derived from Thai medicine plant Mytragyna speciosa. Gen Pharmacol. 1999;33:73–81. - PubMed
    1. Thongpradichote S, Matsumoto K, Tohda M, Takayama H, Aimi N, Saiki S, et al. Identification of opioid receptor subtypes in antinociceptive actions of suprasinallya-dministratered Mitragynine in mice. Life Sci. 1998;62:1371–8. - PubMed
    1. Fishbain D, Rosomoff H. Drug abuse, dependence, and addiction in chronic pain patients. Clin J Pain. 1992;8:77–85. - PubMed
    1. Takayama H, Ishikawa H, Kurihara M, Kitajima M, Aimi N, Ponglux D. Studies on the synthesis and opioid agonistic activities of mitragynine-related indole alkaloids: discovery of opioid agonists structurally different from other opioid ligands. J Med Chem. 2002;45:1949–56. - PubMed

Publication types